Pancreatic cancer is driven by oncogenic KRAS variants in more than 90% of cases [29], and even those cases with wild type KRAS often show alternative alterations that activate oncogenic signaling through the RAS/MAPK pathway [48]. Here, KRAS is linked to pancreatic neoplasm.